Krystle Vermes

A first-of-its-kind blood test delivers an objective diagnosis of major depressive disorder, as well as predicts which adult patients will benefit from cognitive behavioral therapy.

Combined with bolus insulin aspart (NovoLog), insulin degludec (Tresiba) improves long-term glycemic control in children and adolescents with type 1 diabetes.

The FDA has granted priority review to a supplemental New Drug Application that would expand the use of lisdexamfetamine dimesylate (Vyvanse) to treat adult patients with binge eating disorder.

New late-stage trial data show ivabradine reduces cardiovascular death or hospitalization for worsening chronic heart failure in patients with low systolic blood pressure.

Genzyme's alemtuzumab (Lemtrada) and Biogen's dimethyl fumarate (Tecfidera) showed sustained efficacy in a broad range of MS patients.

The FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended against the approval of Actavis' fixed-dose combination of nebivolol and valsartan for the treatment of hypertension.

A single dose of intramuscular peramivir (Rapivab) alleviated the symptoms of influenza in 2 clinical trials.

AstraZeneca's injectable medication to improve glycemic control among adults with type 2 diabetes is now widely available across US pharmacies.

Recent study provides insight into the bacterial cell cycle, shows cell division and DNA replication are not independent.

A model used in 3 studies was found to accurately predict serious complications in patients with type 1 diabetes.

Following recent analysis, researchers found that infants who received HIV vaccines showed immune response to the vaccine.

Vaccine targets the diarrhea-causing bacterium linked to 14,000 US deaths annually.

Vast majority of parents are opting for their young children to receive potentially lifesaving vaccines despite the controversy surrounding their right to refuse such immunizations.

A University of Kentucky pharmacy professor has developed a nasal spray of naloxone (Narcan) to treat potentially fatal overdoses from heroin and prescription opioids.

Aspirin not only prevents the production of pain-causing compounds in the body, but also triggers an enzyme to speed the reduction of inflammation.

Galleon Pharmaceuticals Corp's GAL-021 reverses and prevents respiratory depression associated with opioid use without affecting analgesia.

The Drug Enforcement Administration has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.

Amgen's investigational treatment for secondary hyperparathyroidism in patients with chronic kidney disease who are receiving hemodialysis achieved its primary and secondary endpoints in a second Phase 3 study.

Curcumin, a component of the traditional Indian spice, turmeric, is highly effective in combating the symptoms of major depressive disorder.

In a large-scale trial, Sanofi's Fluzone High-Dose vaccine demonstrated efficacy in preventing influenza specifically in adults aged 65 years or older.

Digoxin increases risk of death in patients with newly diagnosed atrial fibrillation.